# India Thrombus Treatment Market > India Thrombus Treatment Market Research Report By Type (Atrial Thrombus, Venous Thrombus) and By Treatment (Medical Therapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 1,610.8 Million - **2025:** $ 1,716.63 Million - **2035:** $ 3,244.28 Million - **Key Players:** Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), Abbott Laboratories (US), Medtronic plc (IE), Cardinal Health, Inc. (US), Terumo Corporation (JP) **Report ID:** MRFR/HC/51843-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-thrombus-treatment-market-53604 --- ## Market Summary ## **India Thrombus Treatment Market Overview** As per MRFR analysis, the India Thrombus Treatment Market Size was estimated at 1.58 (USD Billion) in 2023.The India Thrombus Treatment Market is expected to grow from 1.61(USD Billion) in 2024 to 6.42 (USD Billion) by 2035. The India Thrombus Treatment Market CAGR (growth rate) is expected to be around 13.394% during the forecast period (2025 - 2035). **Key India Thrombus Treatment Market Trends Highlighted** The rising incidence of thromboembolic illnesses is driving significant developments in the India thrombus treatment market. The prevalence of thrombus-related disorders has increased in the population because to the growth in lifestyle-related health problems like diabetes and obesity. Early identification and diagnosis have increased as a result of the government's emphasis on improved healthcare services and awareness-raising, which encourages people to seek treatment sooner. Furthermore, because they offer efficient treatments with fewer side effects, developments in medical technology and therapeutic approaches—such as the creation of innovative anticoagulants and minimally invasive surgical techniques—act as significant market drivers. The expansion of healthcare infrastructure and the availability of cutting-edge medical facilities in both urban and rural areas are driving additional growth in the India Thrombus Treatment Market. To improve patient outcomes, efforts must be made to improve healthcare personnel' training on thrombus prevention and management. Furthermore, there is a lot of emphasis on research and development to provide novel treatments that target thrombus formation. This creates opportunities for cooperation between the public and private sectors and promotes improvements in treatment alternatives. The treatment of thrombus has recently moved toward personalized medicine as medical professionals try to customize treatments according to the unique characteristics of each patient. Better management of thromboembolic disorders is now possible due to the increased accessibility of consultations and follow-up care brought about by the growing use of telemedicine, particularly in the wake of the pandemic. Additionally, the number of collaborations between pharmaceutical companies and healthcare providers to provide improved disease management solutions is increasing in the Indian healthcare sector. This all-encompassing strategy for treating thrombus-related illnesses demonstrates how the Indian thrombus treatment market is developing due to both innovation and a patient-centered approach. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Thrombus Treatment Market Drivers** **Increasing Prevalence of Cardiovascular Diseases** The rise in cardiovascular diseases in India is a significant driver for the India [Thrombus Treatment Market](../../../reports/thrombus-treatment-market-11453). According to the Indian Heart Association, there has been a noticeable increase in cardiovascular conditions, with around 30% of deaths in India attributed to heart diseases in recent years. With an aging population and lifestyle changes leading to obesity and diabetes, the number of patients requiring thrombus treatment is expected to rise. This trend is further supported by organizations such as the Ministry of Health and Family Welfare, indicating that the burden of heart diseases is likely to continue to escalate. As healthcare infrastructure improves, the demand for effective thrombus treatments will likely increase, contributing to market growth. **Advancements in Medical Technology** Innovations in medical technology are accelerating the development of new thrombus treatment options in the India Thrombus Treatment Market. For instance, the growth of minimally invasive procedures and advanced imaging technologies has made thrombus management more efficient and safer. The Indian government’s initiatives to promote research and development in the healthcare sector are resulting in new treatment modalities. The Digital India campaign also supports technology adoption in healthcare, which has the potential to decrease hospital stay durations and improve patient outcomes, ultimately driving market growth for thrombus treatments. **Rise in Geriatric Population** India is witnessing a demographic shift with a growing geriatric population, leading to an increased incidence of thrombotic disorders. The Ministry of Statistics and Programme Implementation noted that the population aged 60 and above accounted for approximately 8% in 2021, which is projected to rise to 20% by 2050. This demographic is more susceptible to thrombus-related conditions such as strokes and deep vein thrombosis. As healthcare services expand to accommodate this age group, the demand for effective and comprehensive thrombus treatment options will likely surge, driving the India Thrombus Treatment Market significantly. **Government Initiatives and Health Insurance Coverage** Government initiatives to enhance health insurance coverage are bolstering access to thrombus treatments. The Ayushman Bharat scheme, which aims to provide affordable healthcare to a large section of the population, is a notable example. According to recent updates from the National Health Authority, over 10 million individuals have been treated under this scheme since its launch. This increased access to health services leads to higher demand for thrombus treatments, thereby fueling growth in the India Thrombus Treatment Market. Additionally, private insurance companies are also expanding their coverage to include newer thrombus treatment options, enhancing patient reach. **India Thrombus Treatment Market Segment Insights** **Thrombus Treatment Market Type Insights** The India Thrombus Treatment Market is largely categorized by type, which includes Atrial Thrombus and Venous Thrombus. This market classification plays a crucial role in understanding the specific treatment needs and approaches for various thrombotic conditions prevalent in the country. Atrial Thrombus is often associated with conditions like atrial fibrillation, where blood clots form in the heart chambers, leading to significant risks, including stroke. The growing awareness of early detection and effective management of this condition has raised the demand for specialized thrombus treatments in India in recent years. On the other hand, Venous Thrombus encompasses a broader array of ailments such as deep vein thrombosis and pulmonary embolism, which are caused by blood clots in the veins. This segment holds a major share due to the rising incidence of sedentary lifestyles and obesity among the Indian population, highlighting the need for preventive measures and tailored treatment options. Both Atrial and Venous Thrombus segments represent significant areas of growth within the India Thrombus Treatment Market, driven by increasing healthcare expenditure, advancements in medical technologies, and a better understanding of thrombotic disorders. Furthermore, the integration of digital health solutions and telemedicine is expected to bolster patient engagement and thus improve treatment outcomes for both types of thrombolytic stages, reflecting a trend towards personalized medicine in the Indian healthcare landscape. Alongside that, government initiatives aimed at improving cardiovascular health through awareness programs and public health campaigns are likely to further support the expansion of the Atrial and Venous Thrombus segments in the market, ensuring that necessary care reaches those who need it most. This indicates a focused strategy to address the rising incidence of thrombotic conditions and underscores the importance of differentiated treatment approaches based on type within India's broader healthcare strategy. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Thrombus Treatment Market Treatment Insights** The India Thrombus Treatment Market within the Treatment segment is witnessing notable growth driven by increasing incidences of thrombotic disorders, heightened awareness regarding the importance of timely interventions, and advancements in treatment methodologies. Medical Therapy, which encompasses pharmacological interventions, is particularly significant as it addresses both prevention and management of thrombus-related complications, often dominating treatment protocols due to its non-invasive nature and accessibility. Surgery plays a critical role in cases where therapeutic options are insufficient, offering solutions for more complex thrombus formations that require physical removal, thus enhancing patient outcomes. Additionally, the segment identified as Others includes various emerging non-conventional treatments and technologies that cater to patient-specific needs. This segment is witnessing innovation, which is expected to substantially influence the market landscape. As healthcare infrastructure in India continues to improve and government initiatives emphasize advanced treatment options, the Treatment segment is positioned for steady growth overall, contributing significantly to the evolving dynamics of the India Thrombus Treatment Market revenue. **India Thrombus Treatment Market Key Players and Competitive Insights** The India Thrombus Treatment Market has been experiencing significant transformation due to advancements in technology and a rising awareness concerning thrombotic diseases. The competitive landscape in this market is characterized by a range of key players who are focused on the development and introduction of innovative treatment options to satisfy the increasing demand. The growing incidences of thromboembolic disorders, along with an aging population, are further propelling the market. Players in this sector are engaging in extensive research and development initiatives to enhance their product offerings. Furthermore, strategic collaborations, partnerships, and investments in clinical trials are being highlighted by companies aiming to secure a stronger foothold in the Indian market. This competitive environment is crucial for understanding market dynamics and the future trajectory of thrombus treatments in India. Bristol-Myers Squibb operates in the India Thrombus Treatment Market with a strong portfolio of anticoagulants and thrombolytic therapies that address various aspects of thrombus management. The company has built a considerable presence in India, leveraging its global expertise and innovative product lines to enhance patient outcomes. Its robust research capabilities contribute to the development of new treatment modalities tailored for the Indian demographic, positioning Bristol-Myers Squibb as a formidable player in the market. The company's commitment to ongoing clinical research and collaborations with healthcare professionals strengthens its reputation, allowing it to address unmet needs effectively. Bristol-Myers Squibb's well-established distribution networks enable efficient product delivery, thereby ensuring that patients have timely access to critical therapies. Boston Scientific has carved a notable position in the India Thrombus Treatment Market through its advanced medical devices and therapies aimed at thromboembolic complications. The company offers a variety of innovative products including mechanical thrombectomy devices and catheters, which are essential for effective thrombus removal procedures. Boston Scientific's strong market presence in India is underpinned by its strategic approach to addressing local patient needs, thus ensuring that its solutions are both relevant and effective. The company has a track record of successful mergers and acquisitions that have bolstered its capabilities in research and development, enhancing the overall efficacy of its product range. Boston Scientific is focused on advancing technologies and solutions that not only improve patient outcomes but also streamline clinical workflows, solidifying its competitive edge in the Indian market for thrombus treatments. **Key Companies in the India Thrombus Treatment Market Include:** - Bristol-Myers Squibb - Boston Scientific - Abbott - Terumo - Bayer - Roche - Stryker - Johnson & Johnson - GSK - Medtronic - AstraZeneca - Miltenyi Biotec - Sanofi - Novartis - Cardinal Health **India Thrombus Treatment****Market****Developments** In recent months, the India Thrombus Treatment Market has experienced significant developments, particularly with the increasing focus on innovative treatment solutions and the rising prevalence of thromboembolic disorders. In September 2023, Bristol-Myers Squibb announced the successful completion of its clinical trials for a new anticoagulant medication, aiming to reduce the risk of thrombosis in patients. Additionally, in August 2023, Boston Scientific launched its latest endovascular therapy device, enhancing treatment options for various thrombus-related conditions in the Indian market. The market has also seen a notable growth in the valuation of companies such as Medtronic and Abbott, driven by advancements in research and technology. Several companies are collaborating with Indian healthcare institutions to enhance patient access to thrombus treatment, reflecting a commitment to improving healthcare outcomes. Moreover, there was a significant acquisition in July 2023 when Terumo acquired a local company specializing in thrombus treatment delivery systems, which is anticipated to strengthen its operational capabilities in India. Overall, innovations and strategic partnerships are setting a positive trajectory for the India Thrombus Treatment Market, driven by increasing healthcare demands and an emphasis on advanced treatment modalities. **India Thrombus Treatment Market Segmentation Insights** **Thrombus Treatment Market Type Outlook** - Atrial Thrombus - Venous Thrombus **Thrombus Treatment Market Treatment Outlook** - Medical Therapy - Surgery - Others ## Market Drivers ### Growing Awareness and Education The rising awareness regarding thrombus-related health issues among the Indian population is a crucial driver for the thrombus treatment market. Educational campaigns by healthcare organizations and government bodies are informing the public about the risks associated with thrombus formation and the importance of early intervention. This heightened awareness is likely to lead to increased patient consultations and demand for thrombus treatment solutions. Moreover, healthcare professionals are becoming more adept at recognizing thrombus-related conditions, which may result in earlier diagnoses and improved treatment outcomes. As awareness continues to grow, the thrombus treatment market is expected to expand, driven by a more informed patient base seeking effective treatment options. ### Increase in Geriatric Population The demographic shift towards an aging population in India is a significant factor influencing the thrombus treatment market. As the geriatric population increases, the incidence of thrombus-related conditions is likely to rise, given that older adults are at a higher risk for cardiovascular diseases. Current estimates suggest that by 2030, the elderly population in India will reach approximately 300 million, creating a substantial demand for thrombus treatment solutions. This demographic trend is prompting healthcare providers to focus on developing targeted therapies and interventions for older patients. Consequently, the thrombus treatment market is poised for growth as it adapts to meet the needs of this expanding patient demographic. ### Advancements in Medical Technology Technological advancements in medical devices and treatment methodologies are significantly influencing the thrombus treatment market. Innovations such as minimally invasive procedures, advanced imaging techniques, and improved catheter technologies are enhancing the efficacy of thrombus removal and management. For instance, the introduction of thrombectomy devices has shown promising results in clinical settings, leading to better patient outcomes. The market for these devices is projected to grow at a CAGR of around 10% over the next few years. Additionally, the integration of artificial intelligence in diagnostic tools is streamlining the identification of thrombus-related conditions, thereby facilitating timely interventions. These technological improvements are likely to attract investments and drive the thrombus treatment market forward in India. ### Rising Incidence of Cardiovascular Diseases The increasing prevalence of cardiovascular diseases in India is a primary driver for the thrombus treatment market. According to recent health statistics, cardiovascular diseases account for approximately 28% of all deaths in the country. This alarming trend necessitates effective thrombus management strategies, as thrombus formation is a critical factor in many cardiovascular events. The growing awareness among healthcare professionals and patients regarding the importance of timely thrombus treatment is likely to propel market growth. Furthermore, the Indian government's initiatives to improve healthcare access and promote preventive measures may enhance the demand for thrombus treatment solutions. As the population ages and lifestyle-related health issues become more common, the thrombus treatment market is expected to expand significantly in response to these challenges. ### Government Initiatives and Healthcare Policies Government initiatives aimed at improving healthcare infrastructure and access to treatment are pivotal for the thrombus treatment market. The Indian government has launched various health schemes, such as the Ayushman Bharat scheme, which aims to provide affordable healthcare to millions. These initiatives are expected to increase the accessibility of thrombus treatment options for a larger segment of the population. Furthermore, the emphasis on enhancing healthcare facilities in rural areas may lead to a rise in early diagnosis and treatment of thrombus-related conditions. As healthcare policies evolve to prioritize cardiovascular health, the thrombus treatment market is likely to benefit from increased funding and support, fostering growth and innovation in treatment options. ## Future Outlook The [Thrombus Treatment Market](https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453) is projected to grow at a 6.57% CAGR from 2025 to 2035, driven by technological advancements, increasing patient awareness, and rising healthcare expenditure. **New opportunities:** - Development of telemedicine platforms for remote thrombus management - Investment in AI-driven diagnostic tools for early detection - Expansion of outpatient treatment facilities to enhance patient access By 2035, The thrombus treatment market is expected to achieve substantial growth and significant innovations.. ## Segment Insights ### By Type: Atrial Thrombus (Largest) vs. Venous Thrombus (Fastest-Growing) The market share distribution in the India thrombus treatment market is characterized by Atrial Thrombus holding the largest share due to its higher prevalence and significant treatment options. This segment benefits from extensive awareness and better diagnosis, which directly translates to higher treatment demand. On the other hand, the Venous Thrombus segment, although smaller, is rapidly gaining traction as healthcare providers expand their focus on preventive measures and personalized treatment approaches. Growth trends indicate that while Atrial Thrombus remains dominant, the Venous Thrombus segment is positioned for rapid growth owing to increasing incidences linked to lifestyle changes and an aging population. Innovations in treatment options, such as minimally invasive procedures and novel therapeutics, are also driving this growth. The rising prevalence of risk factors such as obesity and immobility further supports the forecasted expansion of the Venous Thrombus segment. Atrial Thrombus: Dominant vs. Venous Thrombus: Emerging Atrial Thrombus is characterized by its critical role in stroke incidences, making it a primary focus for healthcare interventions. This segment encompasses a variety of treatment options including anticoagulants and surgical interventions that cater to a broad patient demographic. Its established nature is supported by a robust supply chain and comprehensive healthcare policies. Conversely, Venous Thrombus, while still emerging, is becoming increasingly relevant due to rising awareness and healthcare initiatives aimed at better management. This segment is seeing advancements in pharmacological treatments and non-invasive therapies which enhance patient recovery and outcomes. The shift towards value-based care is further supporting the growth of both segments in an increasingly competitive market. ### By Treatment: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) The India thrombus treatment market exhibits a diverse treatment approach, with Medical Therapy capturing the largest market share among the segment values. This segment includes various pharmacological interventions that have gained significant traction due to their non-invasive nature and favorable patient outcomes. Surgery, though smaller in market share, is witnessing rapid growth, driven by advancements in surgical techniques and technology, attracting a segment of patients requiring more aggressive interventions. The growth of the Treatment segment is largely influenced by the increasing prevalence of thrombotic disorders, alongside a growing awareness of treatment options among healthcare providers and patients. Additionally, investments in research and development of new therapies are paving the way for innovative solutions in the market. The enhanced access to healthcare and improved diagnostic tools also contribute to the anticipated growth in both Medical Therapy and Surgical interventions. Medical Therapy: Dominant vs. Surgery: Emerging In the competitive landscape of the India thrombus treatment market, Medical Therapy stands out as the dominant segment due to its effectiveness and widespread acceptance. This segment encompasses a variety of anticoagulants and antiplatelet agents that are commonly prescribed for thrombus management, making it the preferred choice for many practitioners. On the other hand, the Surgery segment is emerging rapidly, supported by advancements in minimally invasive surgical procedures and enhanced recovery protocols. These developments are not only improving patient outcomes but also increasing the number of surgical candidates. While Medical Therapy remains at the forefront, the growing shift towards surgical options showcases evolving treatment paradigms and highlights the dynamic nature of the market. ## Competitive Benchmarking The thrombus treatment market in India is characterized by a dynamic competitive landscape, driven by increasing incidences of thromboembolic disorders and a growing emphasis on advanced therapeutic solutions. Key players such as Bayer AG (DE), Bristol-Myers Squibb Company (US), and Johnson & Johnson (US) are strategically positioned to leverage innovation and regional expansion to enhance their market presence. Bayer AG (DE) focuses on developing novel anticoagulants, while Bristol-Myers Squibb Company (US) emphasizes partnerships to broaden its therapeutic portfolio. Johnson & Johnson (US) is actively pursuing digital transformation initiatives to improve patient outcomes, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they engage in strategic collaborations and mergers to enhance their operational capabilities and market reach. In October Bayer AG (DE) announced a collaboration with a leading Indian healthcare provider to enhance access to its novel anticoagulant therapies. This strategic move is likely to improve patient access and adherence to treatment, thereby strengthening Bayer's foothold in the Indian market. The collaboration underscores the importance of local partnerships in navigating the complexities of the healthcare landscape in India. In September Bristol-Myers Squibb Company (US) launched a new digital platform aimed at improving patient engagement and education regarding thrombus treatment options. This initiative is indicative of the company's commitment to leveraging technology to enhance patient outcomes and streamline treatment pathways. By focusing on digital solutions, Bristol-Myers Squibb is positioning itself as a leader in patient-centric care within the thrombus treatment market. In August Johnson & Johnson (US) expanded its product line by introducing a new device designed for the minimally invasive treatment of thrombus. This innovation not only reflects the company's dedication to advancing medical technology but also addresses the growing demand for less invasive treatment options. The introduction of such devices is likely to enhance patient satisfaction and improve clinical outcomes, further solidifying Johnson & Johnson's competitive edge. As of November current trends in the thrombus treatment market include a strong focus on digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This transition may redefine market dynamics, emphasizing the importance of quality and efficacy in thrombus treatment. ## Recent News & Developments In recent months, the India Thrombus Treatment Market has experienced significant developments, particularly with the increasing focus on innovative treatment solutions and the rising prevalence of thromboembolic disorders. In September 2023, Bristol-Myers Squibb announced the successful completion of its clinical trials for a new anticoagulant medication, aiming to reduce the risk of thrombosis in patients. Additionally, in August 2023, Boston Scientific launched its latest endovascular therapy device, enhancing treatment options for various thrombus-related conditions in the Indian market. The market has also seen a notable growth in the valuation of companies such as Medtronic and Abbott, driven by advancements in research and technology. Several companies are collaborating with Indian healthcare institutions to enhance patient access to thrombus treatment, reflecting a commitment to improving healthcare outcomes. Moreover, there was a significant acquisition in July 2023 when Terumo acquired a local company specializing in thrombus treatment delivery systems, which is anticipated to strengthen its operational capabilities in India. Overall, innovations and strategic partnerships are setting a positive trajectory for the India Thrombus Treatment Market, driven by increasing healthcare demands and an emphasis on advanced treatment modalities. ## Report Scope | MARKET SIZE 2024 | 1610.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1716.63(USD Million) | | MARKET SIZE 2035 | 3244.28(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), Abbott Laboratories (US), Medtronic plc (IE), Cardinal Health, Inc. (US), Terumo Corporation (JP) | | Segments Covered | Type, Treatment | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the thrombus treatment market. | | Key Market Dynamics | Rising demand for innovative thrombus treatment solutions driven by regulatory changes and technological advancements in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the overall market valuation of the thrombus treatment market in 2024?** A: The overall market valuation was $1610.8 Million in 2024. **Q: What is the projected market valuation for the thrombus treatment market by 2035?** A: The projected valuation for 2035 is $3244.28 Million. **Q: What is the expected CAGR for the thrombus treatment market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 6.57%. **Q: Which segments are included in the thrombus treatment market?** A: The market includes segments such as Atrial Thrombus, Venous Thrombus, Medical Therapy, Surgery, and Others. **Q: What were the valuations for Atrial and Venous Thrombus in 2024?** A: In 2024, Atrial Thrombus was valued at $644.32 Million, while Venous Thrombus was valued at $966.48 Million. **Q: What are the projected valuations for Medical Therapy and Surgery by 2035?** A: By 2035, Medical Therapy is projected to reach $1600.0 Million, and Surgery is expected to reach $1200.0 Million. **Q: Who are the key players in the thrombus treatment market?** A: Key players include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Roche Holding AG, and Sanofi S.A. **Q: What was the valuation for 'Others' in the treatment segment in 2024?** A: The valuation for 'Others' in the treatment segment was $210.8 Million in 2024. **Q: How does the market for thrombus treatment appear to be evolving?** A: The thrombus treatment market appears to be evolving positively, with a projected growth to $3244.28 Million by 2035. **Q: What might be the implications of the projected growth for stakeholders in the thrombus treatment market?** A: The projected growth could indicate increased opportunities for stakeholders, including pharmaceutical companies and healthcare providers. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-thrombus-treatment-market-53604*